Medtronic (MDT) Q4 2025: Diabetes Spin-Off and Durable Growth Reshape Portfolio for Higher Margins
Medtronic delivered another quarter of mid-single-digit organic revenue growth, translating operational momentum into double-digit EPS gains and announcing a major strategic move to spin off its diabetes business. The company’s focus on high-margin growth drivers in cardiovascular, neuroscience, and surgical robotics is sharpening, with leadership signaling confidence in sustaining and accelerating earnings leverage as the portfolio shifts. Tariff headwinds and margin mix remain watchpoints, but underlying business fundamentals are strengthening as Medtronic reshapes for higher profitability and lower risk.
Summary
- Revenue and EPS Outperformance: Q4 organic revenue grew 5.4% to $8.9B, with adjusted EPS up 11% YoY to $1.62, exceeding expectations.
- Portfolio Transformation: Announced diabetes business spin-off to intensify focus on high-margin, B2B medtech growth areas.
- Growth Drivers Gaining Traction: Cardiac ablation, neuromodulation, structural heart, and surgical robotics all delivered robust, above-market growth.
- Margin and Tariff Headwinds: Product mix, new product launches, and US-China tariffs are expected to pressure gross margin in FY26.
Performance Analysis
Medtronic’s Q4 2025 results reinforce its return to durable top-line expansion and operating leverage, with organic revenue up 5.4% and adjusted EPS up 11% YoY. The quarter capped two and a half years of consistent mid-single-digit growth, demonstrating that recent innovation and portfolio moves are translating into financial results. Cardiovascular led the way, accelerating to 8% growth, driven by nearly 30% growth in Cardiac Ablation Solutions (CAS, a suite of devices for treating cardiac arrhythmias), and double-digit gains in structural heart and cardiac surgery. Neuromodulation and diabetes also posted double-digit growth, while US cranial and spinal technologies grew high single digits.
Geographically, US revenue grew 5%, Japan was up high single digits, and Western Europe and emerging markets delivered mid-single-digit gains. Gross margin fell 70 basis points YoY to 65.1%, mainly due to mix from diabetes and CAS and FX, but was flat on a constant currency basis. Operating margin improved 90 basis points to 27.8%, benefiting from COGS efficiency, pricing discipline, and SG&A leverage, even as R&D investment was increased. Full-year organic revenue growth reached 5%, with EPS up 6% (10% constant currency).
- Cardiac Ablation and Structural Heart Momentum: CAS added 70 basis points to total company growth, with strong demand for Afera PFA products and robust pipeline visibility.
- Diabetes and Neuromodulation Outperform: Both segments delivered double-digit growth, with diabetes up 12% for a sixth consecutive quarter—yet diabetes will be spun off to focus on higher-margin B2B markets.
- Operating Leverage Restored: Adjusted operating profit rose 7.6%, outpacing revenue growth and demonstrating improved cost control and pricing power.
Despite margin headwinds from product mix and tariffs, Medtronic’s underlying earnings power is strengthening, positioning the company to accelerate EPS growth post-diabetes separation.
Executive Commentary
"We had a strong finish to our fiscal year, growing 5.4%. Our growth drivers are having an impact and are still building momentum. We've now delivered mid-single-digit revenue growth for two and a half years. Our cardiovascular growth accelerated, as forecasted, growing 8% on broad strength across the portfolio, including nearly 30% growth in CAS."
Jeff Martha, Chairman and Chief Executive Officer
"Upon full separation [of diabetes], we're expecting our adjusted gross and operating margins to improve by approximately 50 and 100 basis points respectively. Given the share retirement, this separation is expected to be immediately accretive to Medtronic EPS upon completion."
Thierry Piatone, Chief Financial Officer
"Our $2.8 billion diabetes business has strong momentum in a large $16 billion global addressable market. We've delivered double-digit growth now for six consecutive quarters... As an independent company, we will have a shareholder base that is aligned to our business and financial profile."
Q Dallara, EVP and President of Diabetes
Strategic Positioning
1. Diabetes Spin-Off Sharpens Focus and Margin Profile
Medtronic will separate its diabetes unit, which accounted for 8% of FY25 revenue and 4% of segment operating profit, through an IPO and subsequent split-off. This move intensifies Medtronic’s focus on higher-margin, B2B medtech markets—such as cardiac ablation, renal denervation, and surgical robotics—where the company demonstrates scale and operational synergy. The separation is expected to improve gross margin by 50 basis points and operating margin by 100 basis points, with immediate EPS accretion via share retirement.
2. Growth Engines: Cardiac Ablation, Neuroscience, and Robotics
CAS, structural heart, neuromodulation, and surgical robotics are all scaling rapidly, underpinned by robust pipelines and strong customer adoption. The CAS business, now at $1 billion in annual revenue, is expected to double in the near term as new products like Sphere 360 and Pulse Select expand global reach. Neuroscience is leveraging its AbleSpine ecosystem and closed-loop neuromodulation to win share and attract talent, while the Hugo robotic platform is gaining traction in surgical markets.
3. Portfolio Management and Capital Allocation Discipline
Active portfolio management is now a central lever, with leadership signaling continued willingness to divest, acquire, and invest in tuck-in M&A to reinforce core strengths. The diabetes spin-off is consistent with recent exits from ventilation, LVAD, and dialysis, and management is clear that both additions and further subtractions are on the table as they pursue higher growth and profitability.
4. Margin Expansion and Cost Control
Medtronic is delivering operating leverage, with cost of goods sold (COGS) efficiency programs, insourcing, and scrap reduction offsetting inflation and mix headwinds. The new CFO is prioritizing further cost discipline, especially in supply chain and manufacturing, while increasing R&D and targeted sales investments in growth platforms.
5. Navigating External Headwinds: Tariffs and FX
US-China tariffs and FX volatility remain material watchpoints, with $200-350 million in COGS headwind modeled for FY26. Leadership is confident in mitigation efforts but acknowledges ongoing uncertainty. FX is expected to be neutral in FY26 and a potential tailwind in FY27, aided by natural hedges and dynamic pricing strategies.
Key Considerations
Medtronic’s Q4 marks a strategic inflection point, as the company pivots its portfolio toward higher-margin, innovation-led businesses while sustaining broad-based growth. The diabetes spin-off is a capstone to recent portfolio actions, and execution on new product launches and cost control will be critical to maintaining momentum.
Key Considerations:
- Portfolio Reshaping Accelerates: The diabetes separation will sharpen Medtronic’s focus on its strongest, most synergistic franchises and improve its risk and margin profile.
- Durable Growth Drivers: Cardiac ablation, neuromodulation, and robotics are scaling, with robust pipelines and increasing market share in high-growth segments.
- Margin and Tariff Pressures: Product mix (especially early-stage launches in diabetes and CAS) and US-China tariffs are expected to pressure gross margin in FY26, even as operating leverage is restored.
- Capital Allocation Flexibility: Share retirement and higher-margin mix post-spin give Medtronic more room to invest in innovation and tuck-in acquisitions.
- Execution Watchpoints: R&D, sales, and manufacturing investments must deliver on accelerated growth and margin expansion, especially as the company absorbs external headwinds.
Risks
Tariff volatility and product mix shifts are the most immediate risks, with $200-350 million in FY26 COGS exposure to US-China tariffs and margin drag from new product launches. The diabetes spin-off, while accretive, also removes a fast-growing business and increases reliance on successful execution in core B2B segments. Regulatory, reimbursement, and competitive dynamics in key growth areas (like renal denervation and PFA) remain ongoing risks.
Forward Outlook
For Q1 FY26, Medtronic guided to:
- Organic revenue growth of 4.5-5%
- Adjusted EPS of $1.22 to $1.24, with minimal tariff impact and 1-2% FX headwind
For full-year FY26, management guided to:
- Organic revenue growth of approximately 5%
- Adjusted EPS growth of ~4% excluding tariffs, with modeled EPS of $5.50-$5.60 including tariff impact
- Operating profit growth of 7% (excluding tariffs), with increased R&D and targeted sales investments
Management expects to return to high single-digit EPS growth in FY27 post-diabetes separation, driven by continued revenue growth, margin expansion, FX tailwind, and share retirement benefits.
Takeaways
Medtronic is executing a deliberate pivot toward higher-margin, innovation-driven growth, with the diabetes spin-off accelerating portfolio focus and operating leverage. The company’s core franchises are scaling, and leadership is confident in sustaining mid-single-digit revenue growth and restoring double-digit EPS gains as the portfolio shifts. Margin and external headwinds remain, but the business is fundamentally stronger and more resilient.
- Portfolio Shift to High-Margin Growth: Diabetes spin-off will immediately improve margin profile and intensify focus on scalable B2B medtech platforms.
- Growth Engines Delivering: CAS, neuromodulation, and robotics are driving above-market growth, with robust pipelines and strong customer adoption.
- Operational Discipline Restored: Cost control, pricing, and targeted investment are delivering operating leverage even as R&D is scaled up.
- Watchpoints for Investors: Track execution on new launches, tariff mitigation, and further portfolio actions as Medtronic enters a new phase of value creation.
Conclusion
Medtronic’s Q4 results and diabetes spin-off announcement mark a decisive step in its transformation toward a higher-margin, more focused portfolio. With durable growth drivers in place and a sharpened capital allocation strategy, the company is positioned to accelerate earnings growth and reduce risk as it enters FY26 and beyond.
Read-Through
Medtronic’s portfolio realignment and operating leverage turnaround signal broader medtech sector themes: scale, innovation, and margin focus are driving strategic decisions across the industry. The diabetes spin-off reflects a trend toward specialization and capital discipline, while robust growth in cardiac ablation and surgical robotics highlights the premium on differentiated, high-growth platforms. Tariff and FX risk management will remain a sector-wide challenge, and investors should watch for further portfolio actions as companies seek to optimize growth, profitability, and resilience in a shifting macro environment.